This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by McNear, S. Articles by Harrison, S. A. Search for Related Content Social Bookmarking                   What's this?

Review: Current status of therapy in nonalcoholic fatty liver disease

Scott McNear Department of Medicine, Brooke Army Medical Center, San Antonio, TX, USA

Stephen A. Harrison

Scott McNear Department of Medicine, Brooke Army Medical Center, San Antonio, TX, USA, stephen.harrison{at}amedd.army.mil

The obesity epidemic has now spread worldwide. With increase in weight, there is an increase in dysregulated energy metabolism ultimately leading to dysfunction of multiple organ systems recognized as the metabolic syndrome. Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease worldwide, and is thought to be the hepatic manifestation of metabolic syndrome. It is a nondiscriminating disease affecting both children and adults and no socioeconomic class is spared. There is a well-defined increase in both liver-related and all-cause mortality. Current projections foresee a continued worsening in prevalence, especially with the increased rate of childhood obesity. Prevention would be the ultimate goal, but with continued trends in obesity, therapeutic options are needed to manage this chronic liver disease and prevent its complications of cirrhosis and even hepatocellular carcinoma. Therapies will need to be affordable, tolerable, and safe to be useful on such a large scale. This article will discuss some of the basic understanding of NAFLD, as well as review the currently tested therapies, some novel therapies, and potential future therapeutic options.

Key Words: nonalcoholic fatty liver disease • obesity • thiazolidinediones • metformin • HMG Co-A reductase inhibitors • ezetimibe • gemfibrozil • probucol • ursodeoxycholic acid

Therapeutic Advances in Gastroenterology, Vol. 2, No. 1, 29-43 (2009)
DOI: 10.1177/1756283X08100327


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?